Citations 3
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Mattison, Ryan J. , Abdelmessieh, Peter, Burke, Patrick W. , DeAngelo, Daniel J., Dinner, Shira, Fathi, Amir T. , Haddadin, Michael , Kirby, Suzanne, Liedtke, Michaela , Litzow, Mark R. , Long, Meixiao, Luger, Selina M. , Mangan, James K. , Massaro, Stephanie, May, William , Park, Jae H. , Schwartz, Marc S. , Shami, Paul J. , Tomlinson, Benjamin , Webster, Jonathan , Stehman, Katie, Shah, Bijal , Abboud, Ramzi , Aldoss, Ibrahim , DeAngelo, Daniel J. , Gauthier, Jordan , Jain, Nitin , Jonas, Brian A. , Logan, Aaron C , Oluwole, Olalekan O. , Przespolewski, Amanda , Rangaraju, Sravanti , Saygin, Caner , Schwartz, Marc, Awotiwon, Ajibola
Journal of the National Comprehensive Cancer Network | October 16, 2024 | Volume: 22 | Issue: 8 | Pages: 563-576
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) provide recommendations for management of ALL, with a focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. This selection from the NCCN Guidelines for ALL focuses on treatment recommendations for adults with newly diagnosed Ph-negative ALL based on current evidence.
Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Brown, Patrick A. , Aoun, Patricia, Boyer, Michael W., Burke, Patrick W. , Dinner, Shira, Fathi, Amir T. , Kirby, Suzanne, Liedtke, Michaela , Litzow, Mark R. , Luger, Selina M. , Maness, Lori J., Massaro, Stephanie, Mattison, Ryan J. , May, William , Oluwole, Olalekan O. , Park, Jae H. , Uy, Geoffrey L. , Vusirikala, Madhuri , Wieduwilt, Matthew J. , Lynn, Beth, Berardi, Ryan A., Freedman-Cass, Deborah A., Campbell, Mallory, Oluwole, Olalekan O , Uy, Geoffrey , Shah, Bijal , Advani, Anjali S. , DeAngelo, Daniel J. , Gauthier, Jordan , Jain, Nitin , Logan, Aaron C , Przespolewski, Amanda , Rangaraju, Sravanti , Rubnitz, Jeffrey E.
Journal of the National Comprehensive Cancer Network | September 22, 2021 | Volume: 19 | Issue: 9 | Pages: 1079-1109
The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019
Brown, Patrick A. , Wieduwilt, Matthew J. , Wang, Eunice S. , Fathi, Amir T. , Litzow, Mark R. , Aoun, Patricia, Bhatnagar, Bhavana , Boyer, Michael W., Bryan, Teresa , Burke, Patrick W. , Coccia, Peter F., Coutré, Steven , Kirby, Suzanne, Massaro, Stephanie, Mattison, Ryan J. , Oluwole, Olalekan O. , Papadantonakis, Nikolaos , Park, Jae H. , Uy, Geoffrey L. , Gregory, Kristina M., Ogba, Ndiya , Wang, Eunice S. , Oluwole, Olalekan O , Uy, Geoffrey , Logan, Aaron C , DeAngelo, Daniel J. , Cassaday, Ryan D. , Advani, Anjali S. , Jain, Nitin , Liu, Arthur , Rubnitz, Jeffrey E. , Shah, Bijal
Journal of the National Comprehensive Cancer Network | May 22, 2019 | Volume: 17 | Issue: 5 | Pages: 414-423
Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.